CARDIOVASCULAR CO-MORBIDITY

Cardiovascular co-morbidity in Rheumatic

Diseases



Cardiovascular co-morbidity in Rheumatic

Diseases

Introduction

Rheumatic illnesses lead to chronic disability and reduced quality of life for many patients. Rheumatoid arthritis (RA), which is characterized by progressive joint Latvians amatory Polyarthritis damage, occurs about 0.5%-1% of adults in most countries. Spectrum of chronic rheumatic diseases also includes spondiloartrity such as ankylosing spondylitis (AS), psoriasis-related arthropathy and autoimmune disorders, like Systemic Lupus Erythematosus (SLE), systemic sclerosis, systemic vasculitides. Osteoarthritis (OA) is by far the most common chronic joint disease, and it is increasingly recognized as a major contribution to the overall burden of health in society. In addition to their impact on the quality of life and SLE is associated with increased mortality, compared to the general public. The bulk of excess mortality due to cardiovascular diseases (CVD). Proposed clarification for this template, the incidence of cardiovascular disease and mortality are a direct consequence of chronic Latvians ammation and secondary consequences of physical inactivity and drugs used in the management of these diseases, including corticosteroids and nonsteroidal anti Latvians ammatory drugs (NSAIDs) (Gordon, 2002).

Similarities and differences in the nature of vascular disease among patients with RA and SLE can reflect the important concepts in the pathophysiology of atherosclerosis ect and autoimmune functions in this process. There is a need to explore the best preventive strategies for cardiovascular diseases in these patients. In this review we examine the evidence of the risk of cardiovascular disease in patients with rheumatic diseases and proposed mechanisms and to discuss possible strategies for the prevention of cardiovascular diseases in these patients.

Epidemiology of CVD in Patients with Rheumatic Diseases

SLE especially to substantially increase the risk of coronary artery disease, premenopausal women. There is also an increased risk of stroke in patients with SLE, partly because of antiphospholipid Antibody Syndrome coexisting in a subset of patients. Patients with RA have increased incidence of cardiovascular diseases.

The magnitude of the increase varies in the different study differences in case selection and population (Gonzales, et al. 2007). A community-based RA cohorts from southern Sweden, risk of first ever Compensation measures is estimated to increase by 60%, mainly due to an excess of myocardial infarction (MI) (Figure 1). Incidence of MI has been found to increase in a similar way to the men and women with RA Opposite the risk of stroke in this or other groups OF ARMENIA has not increased significantly. This requires that the RA of cardiac pathology can predispose to specifically coronary artery disease and cerebrovascular events that other risk factors such as high blood pressure may be more important. There is some evidence for increasing overall mortality and cardiovascular disease in patients with other rheumatic diseases, such as AU, although data are limited. The same is true for psoriatic arthritis, but the selection bias may be a particular problem in studies of clinical cohorts from this heterogeneous disease.

Sub clinical Atherosclerosis may be more frequent in patients with psoriatic arthritis than the population as a ...